Twenty-four year spironolactone therapy in an aged patient with aldosterone-producing adenoma.

Abstract

A case of primary aldosteronism treated with spironolactone therapy has been followed up for 24 years. This is probably the longest case of spironolactone therapy for primary aldosteronism that has ever been reported. Long-term treatment with spironolactone controlled the hypertension and prevented hypokalemic alkalosis in this patient, without any deleterious effects on steroid biosynthesis. Based on data obtained during dose reduction and subsequent withdrawal of spironolactone, it is suggested that the suppressed plasma renin activity associated with adenoma-induced aldosteronism develops prior to hypokalemia and hypertension.

• Authors: R Takeda, T Yamazaki, Y Ito, H Koshida, T Morise, I Miyamori, T Hashimoto, S Morimoto
• Journal: Acta endocrinologica (Acta Endocrinol (Copenh)) Vol. 126 Issue 2 Pg. 186-90 (Feb 1992) ISSN: 0001-5598 [Print] Denmark
• PMID: 1311894 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Spironolactone
• Aldosterone
• Adrenocorticotropic Hormone
• Renin
• Hydrocortisone

Topics

• Adenoma (complications, drug therapy, pathology)
• Adrenal Gland Neoplasms (complications, drug therapy, pathology)
• Adrenal Glands (pathology)
• Adrenocorticotropic Hormone
• Aged
• Aldosterone (blood)
• Female
• Humans
• Hydrocortisone (blood)
• Hyperaldosteronism (drug therapy, etiology)
• Hypertension (drug therapy, etiology)
• Hypokalemia (etiology)
• Magnetic Resonance Imaging
• Renin (blood)
• Spironolactone (therapeutic use)